



China Pharmaceutical Glass Packaging Industry Report, 2013-2016

Apr. 2014

STUDY GOAL AND OBJECTIVES

This report provides the industry executives with strategically significant competitor information, analysis, insight and projection on the competitive pattern and key companies in the industry, crucial to the development and implementation of effective business, marketing and R&D programs.

REPORT OBJECTIVES

- ◆ To establish a comprehensive, factual, annually updated and cost-effective information base on market size, competition patterns, market segments, goals and strategies of the leading players in the market, reviews and forecasts.
- ◆ To assist potential market entrants in evaluating prospective acquisition and joint venture candidates.
- ◆ To complement the organizations' internal competitor information gathering efforts with strategic analysis, data interpretation and insight.
- ◆ To suggest for concerned investors in line with the current development of this industry as well as the development tendency.
- ◆ To help company to succeed in a competitive market, and

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this study. Initially, a comprehensive and exhaustive search of the literature on this industry was conducted. These sources included related books and journals, trade literature, marketing literature, other product/promotional literature, annual reports, security analyst reports, and other publications.

Subsequently, telephone interviews or email correspondence was conducted with marketing executives etc. Other sources included related magazines, academics, and consulting companies.

INFORMATION SOURCES

The primary information sources include Company Reports, and National Bureau of Statistics of China etc.

Abstract

Influenced by the substitution of plastic, aluminum foil and other new packaging materials as well as the declining packaging material purchase prices incurred by the medical reform, China pharmaceutical glass packaging industry develops sluggishly. In 2013, China's pharmaceutical glass bottle market capacity amounted to 80 billion pieces with the weight of 250,000-300,000 tons.

Due to low entry barriers, Chinese pharmaceutical glass market is featured with serious overcapacity of medium and low-end products as well as the reliance of high-end products on imports. At present, developed countries prefer first-class waterproof neutral borosilicate glass, while China still in the main applies low borosilicate glass, sodium-calcium glass and "semi-neutral borosilicate glass" (its chemical stability can not meet neutral requirements; the heavy metal content in glass is not defined clearly; dimensions are not accurate). As for prefilled injection system glass, China mainly relies on the import from foreign brands such as German Schott.

The report involves the following:

Market size, market demand, competition pattern, import & export and development trend of China pharmaceutical glass industry;
Status quo, competition pattern and price analysis of China prefilled syringe industry;
Operation, pharmaceutical glass business and development prospects of four global and six Chinese pharmaceutical glass packaging enterprises.

After years of development and competition, Chinese pharmaceutical glass market concentration degree is still not high, but there have been competitive leading players in some market segments mainly in Jiangsu, Zhejiang and Shandong.


Shandong Pharmaceutical Glass is the world's fifth and China's first medical glass (Class-I) producer. As one of top five Chinese prefilled syringe suppliers, Shandong Pharmaceutical Glass has the capacity of 50 million units/a, but it is still exploring the market with a rather low market share. Meanwhile, the company is a leading pharmaceutical molded bottle enterprise in China with the capacity of 10 billion units/a and about 70% market share.

Weigao is also one of the top five Chinese prefilled syringe suppliers. By virtue of preemptive advantages and perfect sales networks, Weigao sold 70 million prefilled syringes in 2013, holding about 60% market share in China.

German Schott has transferred from simple high-end pharmaceutical glass raw material supply to the combination of raw material supply and joint production of finished products. Its joint venture in China -- Schott Xin Kang Pharmaceutical Packaging Co., Ltd. can produce 1-1.5 billion pharmaceutical glass bottles (vials and ampule bottles) each year.

Germany Gerresheimer conducts Plastic Systems, Molded Glass, Tubular Glass and Life Science Research in China. However, the prefilled syringes from the company in China are not made in China but imported. In addition, Gerresheimer and Shuangfeng Glass founded a high-end medical packaging material joint venture -- Gerresheimer Shuangfeng that has two subsidiaries located in Danyang city and Zhenjiang city, as well as three production sites (two in Danyang and one in Zhenjiang).

Competitive Edges of Key Pharmaceutical Glass Enterprises in China



1 Overview of Pharmaceutical Glass Packaging Materials

- 1.1 Definition and Classification
- 1.2 Industry Chain

2 Development of China Pharmaceutical Glass Industry

- 2.1 Status Quo
- 2.2 Market Size
- 2.3 Competition Pattern
- 2.4 Import and Export
- 2.5 Prefilled Syringe
 - 2.5.1 Definition and Classification
 - 2.5.2 Status Quo
 - 2.5.3 Competition Pattern
 - 2.5.4 Price Analysis
- 2.6 Development Trend

3 Major Pharmaceutical Glass Enterprises

- 3.1 Becton, Dickinson and Company
 - 3.1.1 Profile
 - 3.1.2 Operation
 - 3.1.3 Revenue Structure
 - 3.1.4 Pharmaceutical Packaging Materials Business
 - 3.1.5 Business in China
- 3.2 Gerresheimer AG
 - 3.2.1 Profile
 - 3.2.2 Operation

- 3.2.3 Revenue Structure
- 3.2.4 Business in China
- 3.3 SCHOTT AG
 - 3.3.1 Profile
 - 3.3.2 Pharmaceutical Packaging Materials Business
 - 3.3.3 Business in China
- 3.4 Nipro Medical Corporation
 - 3.4.1 Profile
 - 3.4.2 Operation
 - 3.4.3 Revenue Structure
 - 3.4.4 Pharmaceutical Packaging Materials Business
 - 3.4.5 Business in China
- 3.5 Shandong Pharmaceutical Glass
 - 3.5.1 Profile
 - 3.5.2 Operation
 - 3.5.3 Revenue Structure
 - 3.5.4 Gross Margin
 - 3.5.5 Prospects and Forecast
- 3.6 Weigao
 - 3.6.1 Profile
 - 3.6.2 Operation
 - 3.6.3 Revenue Structure
 - 3.6.4 Gross Margin
 - 3.6.5 R & D and Investment
 - 3.6.6 Major Clients
 - 3.6.7 Pharmaceutical Packaging Materials Business
 - 3.6.8 Prospects and Forecast

- 3.7 Cangzhou Four Stars Glass
- 3.8 Min Kang Pharmaceutical
- 3.9 ChongQing ZhengChuan Glass
- 3.10 Linuo Group

- 
- Classification and Application of Pharmaceutical Glass
 - New-type Pharmaceutical Glass Packaging and Application
 - Pharmaceutical Glass Packaging Industry Chain
 - Output of Human Powder (Including Lyophilized Powder) and Injection in China, 2010-2013
 - China's Human LVP Output, 2010-2013
 - Revenue and YoY Growth Rate of Chinese Veterinary Drug industry, 2007-2013
 - China's Glass Ampule Import and Export Volume, 2011-2013
 - China's Glass Ampule Import and Export Value, 2011-2013
 - China's Glass Ampule Import and Export Average Price, 2011-2013
 - Prefilled Syringe-use Materials
 - Prefilled Syringe Classification and Structure
 - Chinese Prefilled Syringe Suppliers and Their Products
 - Major Chinese Prefilled Enterprises and Their Capacity, 2013
 - Prices of Some Chinese Prefilled Pharmaceutical Packaging Products, 2010-2013
 - BD's Main Businesses
 - BD's Revenue and Operating Profit, FY2010-FY2013
 - BD's Revenue Structure (by Business), FY2012-FY2013
 - BD's Revenue Structure (by Region), FY2012-FY2013
 - BD's Medical Revenue (by Product), FY2011-FY2013
 - Gerresheimer's Revenue Structure (by Consumer Market), 2012
 - Gerresheimer's Revenue and Operating Profit, 2009-2013
 - Gerresheimer's Revenue (by Business), 2009-2013
 - Gerresheimer's Revenue Structure (by Region), 2012
 - Schott's Subsidiaries in China
 - Nipro's Revenue and Net Income, FY2010-FY2013

- 
- Nipro's Revenue Structure (by Business), FY2012-FY2013
 - Nipro's Revenue Structure (by Region), FY2013
 - Nipro's Glassware Revenue and % in Total Revenue, FY2012-FY2013
 - Nipro's Main Subsidiaries and Business in China
 - Main Products of Shandong Pharmaceutical Glass
 - Revenue and Net Income of Shandong Pharmaceutical Glass, 2008-2013
 - Operating Revenue of Shandong Pharmaceutical Glass (by Product), 2008-2013
 - Operating Revenue of Shandong Pharmaceutical Glass (by Region), 2008-2013
 - Gross Margin of Shandong Pharmaceutical Glass (by Product), 2008-2013
 - Revenue and Gross Margin of Shandong Pharmaceutical Glass (by Product), 2012-2016E
 - Weigao's Product Categories and Major Products
 - Weigao's Revenue and Net Income, 2009-2013
 - Weigao's Sales and Distribution Network, 2012
 - Output of Weigao's Main Products, 2011-2013
 - Weigao's Revenue Structure (by Product), 2009-2013
 - Revenue Structure of Weigao's Regular Medical Supplies, 2006-2013
 - Main High-value-added Products of Weigao's Regular Medical Supplies
 - Weigao's Revenue (by Region), 2008-2013
 - Weigao's Prefilled Syringe Output and Sales Revenue, 2011-2013

You can place your order in the following alternative ways:

1. Order online at www.researchinchina.com
2. Fax order sheet to us at fax number: +86 10 82601570
3. Email your order to: report@researchinchina.com
4. Phone us at +86 10 82600828/ 82601561

Party A:			
Name:			
Address:			
Contact Person:		Tel	
E-mail:		Fax	

Party B:			
Name:	Beijing Waterwood Technologies Co., Ltd (ResearchInChina)		
Address:	Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080		
Contact Person:	Liao Yan	Phone:	86-10-82600828
E-mail:	report@researchinchina.com	Fax:	86-10-82601570
Bank details:	Beneficial Name: Beijing Waterwood Technologies Co., Ltd Bank Name: Bank of Communications, Beijing Branch Bank Address: NO.1 jinxiyuan shijicheng, Landianchang, Haidian District, Beijing Bank Account No #: 110060668012015061217 Routing No #: 332906 Bank SWIFT Code: COMMCNSHBJG		

Title	Format	Cost
Total		

Choose type of format

PDF (Single user license) 1,500 USD
 Hard copy 1,600 USD
 PDF (Enterprisewide license)..... 2,300 USD

※ Reports will be dispatched immediately once full payment has been received.
 Payment may be made by wire transfer or credit card via PayPal.

About ResearchInChina

ResearchInChina (www.researchinchina.com) is a leading independent provider of China business intelligence. Our research is designed to meet the diverse planning and information needs of businesses, institutions, and professional investors worldwide. Our services are used in a variety of ways, including strategic planning, product and sales forecasting, risk and sensitivity management, and as investment research.

Our Major Activities

- ❑ *Multi-users market reports*
- ❑ *Database-RICDB*
- ❑ *Custom Research*
- ❑ *Company Search*

RICDB (<http://www.researchinchina.com/data/database.html>), is a visible financial data base presented by map and graph covering global and China macroeconomic data, industry data, and company data. It has included nearly 500,000 indices (based on time series), and is continuing to update and increase. The most significant feature of this base is that the vast majority of indices (about 400,000) can be displayed in map.

After purchase of our report, you will be automatically granted to enjoy 2 weeks trial service of RICDB for free.

After trial, you can decide to become our formal member or not. We will try our best to meet your demand. For more information, please find at www.researchinchina.com

For any problems, please contact our service team at: